The Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market is expected to reach $49.2 billion by 2030 at a CAGR of 8.9% from 2023 to 2030. Pharmaceutical contract development and manufacturing organizations offer various services based on a contract to small or large pharmaceutical companies. These services include active pharmaceutical ingredient (API) manufacturing, finished dosage form (FDF) manufacturing, drug development & drug discovery services, and biologics manufacturing services. The COVID-19 pandemic positively impacts the pharmaceutical contract development and manufacturing market due to the increased demand for pharmaceutical products such as tablets, capsules, drugs, and vaccines.
The growth of the Asia-Pacific pharmaceutical contract development and manufacturing market is attributed to the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, and the rising demand for generic medicines & biologics. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market. However, the lack of skilled professionals and the introduction of serialization are some of the challenges to the growth of this market.
The pharmaceutical industry is largely driven by scientific discovery, development, and toxicological and clinical experience. Pharmaceutical manufacturing operations may be categorized as primary production of bulk drug substances (APIs) and manufacturing of dosage form products (formulations).
In addition to the complexity of the pharmaceutical manufacturing process, many countries globally have specific legal protections for proprietary drugs and manufacturing processes, known as intellectual property rights. When legal protections are limited or nonexistent, some companies specialize in manufacturing and marketing generic drugs. The pharmaceutical industry requires large capital investments due to the high expenses associated with R&D, regulatory approvals, manufacturing, quality assurance & control, marketing, and sales.
Many countries have extensive government regulations affecting the development and approval of drugs for commercial sale. These countries have strict requirements for good manufacturing practices to ensure the integrity of drug manufacturing operations and pharmaceutical products' quality, safety, and efficacy. These challenges have led pharmaceutical companies to partner with contract manufacturing and development organizations to develop and manufacture pharmaceuticals and biologics, driving the growth of the pharmaceutical contract development and manufacturing market.
Click here to: Get Free Sample Pages of this Report
The increasing prevalence of cancer, autoimmune, cardiovascular, and infectious diseases in Asia-Pacific has resulted in the emergence of biopharmaceuticals or biologics as an important therapeutic class for treating these diseases. Biologics offer numerous advantages over synthetic drugs by targeting specific sites and rarely causing side effects, resulting in the increasing number of approvals and the demand for biologics, such as therapeutic proteins and monoclonal antibodies (MAbs).
According to GLOBOCAN, in Asia, the cancer cases in 2020 were 9,503,710 million, which is expected to increase by 59.2% by 2040. Furthermore, the COVID-19 pandemic, the Ebola epidemic, and the rising incidences of infectious diseases significantly burden the healthcare sector and boost the demand for vaccines. For instance, in 2020, the outbreak of the COVID-19 pandemic imposed a huge burden on the pharmaceutical industry and increased the demand for vaccines and breakthrough drugs. Due to this increase, the demand for biopharmaceutical products has risen with the subsequent growth in the Asia-Pacific pharmaceutical contract development and manufacturing market.
Key Findings of the Market Study:
In 2023, the Pharmaceutical Manufacturing Services Segment is Expected to Dominate this Market
Based on type, the Asia-Pacific pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing services, drug development services, and biologics manufacturing services. In 2023, the pharmaceutical manufacturing services segment is expected to account for the largest share of the market. The pharmaceutical manufacturing services segment is further segmented into active pharmaceutical ingredient (API) manufacturing services and finished dosage forms (FDF) manufacturing services. The largest share of this segment is attributed to the need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing and the growing demand for generic drugs. Additionally, contract manufacturing organizations conduct the manufacturing process by governing all the environmental and regulatory norms driving the market.
In 2023, the Large Pharmaceutical Companies Segment is Expected to Account for the Largest Share of the Market
Based on end user, the Asia-Pacific pharmaceutical contract development and manufacturing market is segmented into large pharmaceutical companies, small & mid-size pharmaceutical companies, and generic pharmaceutical companies. In 2023, the large pharmaceutical companies segment is expected to account for the largest share of the market. Factors such as the increasing need for cost control amid increasing pricing pressure, rising complex manufacturing requirements and inclination towards cutting-edge technologies, and sponsors strategically focusing on core business functions such as marketing & R&D support the largest share of the market.
Japan: Fastest Growing Market
Japan is expected to register the highest CAGR during the forecast period. Capacity expansion by key pharmaceutical manufacturers, favorable government regulations supporting the approval of new pharmaceuticals, and the prevalence of chronic illness and other infectious diseases amid the growing geriatric population are the major drivers for the Japanese pharmaceutical contract development and manufacturing market. According to the Population Division, Department of Economic and Social Affairs (DESA), United Nations, in Japan, the percentage of the population aged 65 and above has dramatically increased. It is estimated that this population will account for 37.3% of the total population in Japan by 2030, compared to 23.3% in 2000. This significant growth in the geriatric population has increased the burden of chronic diseases such as cancer and cardiovascular diseases, driving the need for contract development and manufacturing.
Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the Asia-Pacific pharmaceutical contract development and manufacturing market are Samsung Biologics Co., Ltd. (South Korea), FUJIFILM Diosynth Biotechnologies (Japan), AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Piramal Enterprises Limited (India), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Jubilant Life Sciences Limited (India), IDT Australia (Australia), Nipro Pharma Corporation (Japan), Shanghai ChemPartner Co., Ltd. (China), and Aurobindo Pharma, Ltd. (India).
Scope of the Report:
Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment, by Type
Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment, by End User
Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment , by Country
Key questions answered in the report:
The Asia-Pacific pharmaceutical contract development and manufacturing market studies different types of services, such as pharmaceutical manufacturing services, drug development services, and biologics manufacturing services used by end users. The Asia-Pacific pharmaceutical contract development and manufacturing market studied in this report involves the analysis of various segments at country levels.
The Asia-Pacific pharmaceutical contract development and manufacturing market is projected to reach $49.2 billion by 2030 at a CAGR of 8.9% from 2023 to 2030
Among all the types studied in the report, the pharmaceutical manufacturing services segment is expected to account for the largest share of the market in 2023. The largest share of the segment is attributed to the growing need to reduce manufacturing costs, to bring a new drug to the market quickly at the lowest possible cost, the requirement for high-quality bulk manufacturing and the growing demand for generic drugs.
The growth of this market is driven by the complex manufacturing requirements of the pharmaceutical industry, manufacturers' growing inclination toward the use of cutting-edge technologies, patent expiration, increasing investments in pharmaceutical R&D, and the rising demand for generic medicines & biologics. In addition, the growing demand for cell and gene therapies and personalized medicines and growth in high potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets is expected to offer significant opportunities for the growth of the pharmaceutical contract development and manufacturing market.
The key players operating in the Asia-Pacific pharmaceutical contract development and manufacturing market are Samsung Biologics Co., Ltd. (South Korea), FUJIFILM Diosynth Biotechnologies (Japan), AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn Ag & Co. KG. (Germany), Piramal Enterprises Limited (India), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Jubilant Life Sciences Limited (India), IDT Australia (Australia), Nipro Pharma Corporation (Japan), Shanghai ChemPartner Co., Ltd. (China), and Aurobindo Pharma, Ltd. (India)
China and Japan are expected to offer significant growth opportunities owing to the government initiatives to create favorable pharmaceutical drug approval programs, increase investment from existing pharmaceutical manufacturers in the country for infrastructure development, and grow investments towards biosimilar manufacturing.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Complex Manufacturing Requirements of the Pharmaceutical Industry
4.2.2. Manufacturers' Growing Inclination Toward the Use of Cutting-Edge Technologies
4.2.3. Rising Demand for Generic Medicines and Biologics
4.2.4. Patent Expiration
4.2.5. Increasing Investments in Pharmaceutical R&D
4.3. Restraints
4.3.1. Stringent Regulatory Requirements
4.4. Opportunities
4.4.1. Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
4.4.2 Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
4.5. Challenges
4.5.1. Shortage of Skilled Professionals
4.5.2. Introduction of Serialization
4.6. Trends
4.6.1 Virtual Business Models
4.6.2. Growing Consolidation Among CDMO Market Players
4.7. Factor Analysis
4.8. Regulatory Analysis
4.9. Porter’s 5 Force Analysis
5. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment—Type
5.1. Overview
5.2. Pharmaceutical Manufacturing Services
5.2.1. Active Pharmaceutical Ingredient (API) Manufacturing Services
5.2.2. Finished Dosage Forms (FDF) Manufacturing Services
5.2.2.1. Parenteral/Injectable Manufacturing Services
5.2.2.2. Tablet Manufacturing Services
5.2.2.3. Capsule Manufacturing Services
5.2.2.4. Oral Liquid Manufacturing Services
5.2.2.5. Other Formulations
5.3. Drug Development Services
5.4. Biologics Manufacturing Services
5.4.1. Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
5.4.2. Finished Dosage Form Manufacturing (FDF) Services
6. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment—by End User
6.1. Overview
6.2. Large Pharmaceutical Companies
6.3. Small & Mid-Size Pharmaceutical Companies
6.4. Generic Pharmaceutical Companies
7. Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market Assessment–by Geography
7.1. Overview
7.2. China
7.3. Japan
7.4. India
7.5. South Korea
7.6. Australia
7.7. Singapore
7.8. Rest of Asia Pacific
8. Competition Analysis
8.1. Overview
8.2. Competitive Dashboard
8.2.1. Industry Leaders
8.2.2. Market Differentiators
8.2.3. Vanguards
8.2.4. Emerging Companies
8.3. Vendor Market Positioning
8.4. Market Share Analysis/Market Ranking (2022)
9. Company Profiles (Company Overview, Financial Snapshot, Product Portfolio, Strategic Developments, SWOT Analysis for the Top 5 Companies)
9.1. Samsung Biologics Co., Ltd.
9.2. FUJIFILM Diosynth Biotechnologies
9.3. AbbVie Inc.
9.4. Aenova Group
9.5. Wuxi Biologics, Inc.
9.6. Vetter Pharma International GmbH
9.7. Catalent, Inc
9.8. Lonza Group Ltd.
9.9. Recipharm AB
9.10. Almac Group
9.11. C.H. Boehringer Sohn Ag & Co. KG.
9.12 Piramal Enterprises Limited
9.13. Eurofins Scientific
9.14. Curia Global, Inc.
9.15. Thermo Fisher Scientific, Inc.
9.16. Evonik Industries AG
9.17. Jubilant Life Sciences Limited
9.18. IDT Australia
9.19. Nipro Pharma Corporation
9.20 Shanghai ChemPartner Co., Ltd.
9.21. Aurobindo Pharma, Ltd.
10. Appendix
10.1. Available Customization
10.2. Related Reports
List of Tables
Table 1 Asia-Pacific Pharmaceutical Manufacturing Services Market, by Type, 2021–2030 (USD Million)
Table 2 Asia-Pacific Pharmaceutical Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 3 Asia-Pacific Active Pharmaceutical Ingredient (API) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 4 Asia-Pacific Finished Dosage Forms (FDF) Manufacturing Services Market, by Type, 2021–2030 (USD Million)
Table 5 Asia-Pacific Finished Dosage Forms (FDF) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 6 Asia-Pacific Parenteral/Injectable Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 7 Asia-Pacific Tablet Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 8 Asia-Pacific Capsule Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 9 Asia-Pacific Oral Liquid Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 10 Asia-Pacific Other Formulations Market, by Country, 2021–2030 (USD Million)
Table 11 Asia-Pacific Drug Development Services Market, by Country, 2021–2030 (USD Million)
Table 12 Asia-Pacific Biologics Manufacturing Services, by Type, 2021–2030 (USD Million)
Table 13 Asia-Pacific Biologics Manufacturing Services, by Country, 2021–2030 (USD Million)
Table 14 Asia-Pacific Active Pharmaceutical Manufacturing Services (API) Manufacturing Services Market, by Country, 2021–2030 (USD Million)
Table 15 Asia-Pacific Finished Dosage Form Manufacturing (FDF) Services Market, by Country, 2021–2030 (USD Million)
Table 16 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 17 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Large Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 18 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Small & Mid-Size Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 19 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market for Generic Pharmaceutical Companies, by Country, 2021–2030 (USD Million)
Table 20 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Country., 2021-2030 (USD Million)
Table 21 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 22 Asia-Pacific: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 23 Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 24 Asia-Pacific: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 25 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 26 China: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 27 China: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 28 China: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 29 China: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 30 China: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 31 Japan: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 32 Japan: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 33 Japan: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 34 Japan: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 35 Japan: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 36 India: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 37 India: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 38 India: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 39 India: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 40 India: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 41 South Korea: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 42 South Korea: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 43 South Korea: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 44 South Korea: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 45 South Korea: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 46 Australia: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 47 Australia: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 48 Australia: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 49 Australia: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 50 Australia: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 51 Singapore: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 52 Singapore: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 53 Singapore: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 54 Singapore: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 55 Singapore: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 56 Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by Type, 2021–2030 (USD Million)
Table 57 Rest of Asia-Pacific: Pharmaceutical Manufacturing Services Market, 2021–2030 (USD Million)
Table 58 Rest of Asia-Pacific: Finished Dosage Forms (FDF) Manufacturing Services Market, 2021–2030 (USD Million)
Table 59 Rest of Asia-Pacific: Biologics Manufacturing Services Market, 2021–2030 (USD Million)
Table 60 Rest of Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market, by End User, 2021–2030 (USD Million)
Table 61 Recent Developments, by Company, 2020—2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Type, 2023 VS. 2030 (USD Million)
Figure 8 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2023 VS. 2030 (USD Million)
Figure 9 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Type, 2023 VS. 2030 (USD Million)
Figure 10 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by End User, 2023 VS. 2030 (USD Million)
Figure 11 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market, by Country, 2023 VS. 2030 (USD Million)
Figure 12 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Snapshot
Figure 13 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 14 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Competitive Dashboard
Figure 15 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Type
Figure 16 Asia-Pacific Pharmaceutical Contract Development and Manufacturing Market: Market Share Analysis (2022)
Figure 17 Samsung Biologics Co., Ltd.: Financial Snapshot (2022)
Figure 18 FUJIFILM Diosynth Biotechnologies: Financial Snapshot (2022)
Figure 19 AbbVie Inc.: Financial Snapshot (2022)
Figure 20 Aenova Group.: Financial Snapshot (2022)
Figure 21 Wuxi Biologics, Inc.: Financial Snapshot (2022)
Figure 22 Catalent, Inc.: Financial Snapshot (2022)
Figure 23 Lonza Group Ltd.: Financial Snapshot (2022)
Figure 24 Recipharm AB: Financial Snapshot (2022)
Figure 25 C.H. Boehringer Sohn Ag & Co. KG..: Financial Snapshot (2022)
Figure 26 Piramal Enterprises Limited.: Financial Snapshot (2022)
Figure 27 Eurofins Scientific.: Financial Snapshot (2022)
Figure 28 Thermo Fisher Scientific, Inc., IncFinancial Snapshot (2022)
Figure 29 Evonik Industries AG: Financial Snapshot (2022)
Figure 30 Jubilant Life Sciences Limited: Financial Snapshot (2022)
Figure 31 IDT Australia: Financial Snapshot (2022)
Figure 32 Aurobindo Pharma, Ltd.: Financial Snapshot (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Aug-2023
